Advertisement

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

David A. Hyman, MD, JD, on Inclusive Shared Savings

Opportunities to Optimize Cancer Policies Panel Discussion

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Advertisement

Advertisement

Aug

04

Today In Oncology

TOPAZ-1 Post Hoc Analysis Supports Durvalumab Plus Chemotherapy in Advanced Biliary Tract Cancer

FDA Approves Radionuclide Therapy Plus ARPI for mAPMN/S Prostate Cancer

Quantum Machine Learning Framework Improves Prediction of Antigen Presentation and Immunotherapy Response

Researchers Identify Donor NK Cell Subset That Impairs CAR NK Cell Therapy and Demonstrate a Manufacturing Solution

Enfortumab Vedotin Plus Pembrolizumab Improves Outcomes in Cisplatin-Eligible Muscle-Invasive Bladder Cancer

Advertisement

© 2026 HSP News Service, L.L.C.